Fmr LLC Sells 45,207 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

FMR LLC decreased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,076,445 shares of the biopharmaceutical company's stock after selling 45,207 shares during the period. FMR LLC owned 10.42% of Intra-Cellular Therapies worth $925,105,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in Intra-Cellular Therapies by 1.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company's stock valued at $1,614,000 after acquiring an additional 283 shares in the last quarter. Captrust Financial Advisors boosted its position in Intra-Cellular Therapies by 47.0% in the third quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company's stock valued at $589,000 after buying an additional 2,572 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth approximately $280,000. Janus Henderson Group PLC raised its stake in shares of Intra-Cellular Therapies by 6.4% in the third quarter. Janus Henderson Group PLC now owns 42,729 shares of the biopharmaceutical company's stock valued at $3,126,000 after acquiring an additional 2,568 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after acquiring an additional 56,664 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Piper Sandler reiterated a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price target for the company from $119.00 to $132.00 in a report on Friday, January 31st. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock remained flat at $131.87 during trading hours on Friday. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.98. The company has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. The business has a 50-day simple moving average of $130.29 and a 200 day simple moving average of $104.37.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.